<SEC-DOCUMENT>0001564590-23-007437.txt : 20230525
<SEC-HEADER>0001564590-23-007437.hdr.sgml : 20230525
<ACCEPTANCE-DATETIME>20230525163100
ACCESSION NUMBER:		0001564590-23-007437
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20230525
DATE AS OF CHANGE:		20230525

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Alkermes plc.
		CENTRAL INDEX KEY:			0001520262
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				981007018
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35299
		FILM NUMBER:		23961212

	BUSINESS ADDRESS:	
		STREET 1:		CONNAUGHT HOUSE
		STREET 2:		1 BURLINGTON ROAD
		CITY:			DUBLIN 4
		STATE:			L2
		ZIP:			00000
		BUSINESS PHONE:		00-353-1-772-8000

	MAIL ADDRESS:	
		STREET 1:		CONNAUGHT HOUSE
		STREET 2:		1 BURLINGTON ROAD
		CITY:			DUBLIN 4
		STATE:			L2
		ZIP:			00000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ANTLER SCIENCE TWO PLC
		DATE OF NAME CHANGE:	20110804

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Antler Science Two Ltd
		DATE OF NAME CHANGE:	20110509
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>alks-defa14a_20230525.htm
<DESCRIPTION>DEFA14A
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
alks-defa14a_20230525.htm
</title>
</head>
<!-- NG Converter v5.0.2.73 -->
<body>

<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Washington, D.C. 20549</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:8pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SCHEDULE 14A</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Proxy Statement Pursuant to Section 14(a) of<br />the Securities Exchange Act of 1934 (Amendment No. &#160;&#160;&#160;&#160;)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:1pt;">
<td valign="top"  style="width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:4.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;">&nbsp;</p></td>
<td valign="top"  style="width:90.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="4" valign="top"  style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Filed by the Registrant&#160;&#160;<font style="font-family:'Times New Roman';"><font style="font-size:9pt;font-family:'Times New Roman'">&#9746;</font></font></p></td>
</tr>
<tr>
<td colspan="4" valign="top"  style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="4" valign="top"  style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Filed by a Party other than the Registrant&#160;&#160;<font style="font-family:'Times New Roman';"><font style="font-size:9pt;font-family:'Times New Roman'">&#9744;</font></font></p></td>
</tr>
<tr>
<td colspan="4" valign="top"  style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="4" valign="top"  style="width:100%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Check the appropriate box:</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:9pt;font-family:'Times New Roman'">&#9744;</font></p></td>
<td colspan="3" valign="top"  style="width:94.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preliminary Proxy Statement</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:9pt;font-family:'Times New Roman'">&#9744;</font><font style="font-family:Times New Roman;">&nbsp;</font></p></td>
<td colspan="3" valign="top"  style="width:94.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:9pt;font-family:'Times New Roman'">&#9744;</font></p></td>
<td colspan="3" valign="top"  style="width:94.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Definitive Proxy Statement</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:9pt;font-family:'Times New Roman'">&#9746;</font></p></td>
<td colspan="3" valign="top"  style="width:94.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Definitive Additional Materials</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:9pt;font-family:'Times New Roman'">&#9744;</font></p></td>
<td colspan="3" valign="top"  style="width:94.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Soliciting Material under &#167;240.14a-12</p></td>
</tr>
<tr>
<td colspan="4" valign="top"  style="width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="4" valign="top"  style="width:100%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ALKERMES PLC</p></td>
</tr>
<tr>
<td colspan="4" valign="top"  style="width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Name of Registrant as Specified In Its Charter)</p></td>
</tr>
<tr>
<td colspan="4" valign="top"  style="width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="4" valign="top"  style="width:100%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="4" valign="top"  style="width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Name of Person(s) Filing Proxy Statement, if other than the Registrant)</p></td>
</tr>
<tr>
<td colspan="4" valign="top"  style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="4" valign="top"  style="width:100%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payment of Filing Fee (Check the appropriate box):</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.04%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:9pt;font-family:'Times New Roman'">&#9746;</font></p></td>
<td colspan="3" valign="top"  style="width:94.96%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No fee required.</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.04%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:9pt;font-family:'Times New Roman'">&#9744;</font></p></td>
<td colspan="3" valign="top"  style="width:94.96%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.04%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:4.66%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</p></td>
<td valign="top"  style="width:90.3%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title of each class of securities to which transaction applies:</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:4.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:90.3%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.04%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:4.66%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</p></td>
<td valign="top"  style="width:90.3%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Aggregate number of securities to which transaction applies:</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:4.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:90.3%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.04%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:4.66%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</p></td>
<td valign="top"  style="width:90.3%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:4.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:90.3%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.04%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:4.66%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4)</p></td>
<td valign="top"  style="width:90.3%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proposed maximum aggregate value of transaction:</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:4.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:90.3%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.04%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:4.66%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5)</p></td>
<td valign="top"  style="width:90.3%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total fee paid:</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:4.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:90.3%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.04%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:9pt;font-family:'Times New Roman'">&#9744;</font></p></td>
<td colspan="3" valign="top"  style="width:94.96%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fee paid previously with preliminary materials.</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.04%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:9pt;font-family:'Times New Roman'">&#9744;</font><font style="font-family:Times New Roman;">&nbsp;</font></p></td>
<td colspan="3" valign="top"  style="width:94.96%;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</p></td>
<td colspan="2" valign="top"  style="width:90.6%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amount Previously Paid:</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</p></td>
<td colspan="2" valign="top"  style="width:90.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Form, Schedule or Registration Statement No.:</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</p></td>
<td colspan="2" valign="top"  style="width:90.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Filing Party:</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4)</p></td>
<td colspan="2" valign="top"  style="width:90.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:5pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date Filed:</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a>On May 25, 2023, Alkermes plc (the &#8220;Company") issued the following press release in connection with the Company's 2023 annual general meeting of shareholders, which contains a copy of a letter to shareholders issued by the Company's board of directors. A copy of the press release can be found below:</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Alkermes Files Definitive Proxy Statement and Issues Letter to Shareholders Detailing </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Business Execution That Has Driven Strong Performance and Delivered Shareholder Value </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Calibri;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Company Has Outperformed Peers and Relevant Indices Since Unveiling its December 2020 Value Enhancement Plan </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Calibri;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">70% of Board&#8217;s Independent Directors Have Been Appointed Over the Last Four Years, Including Four Directors Designated or Supported by Shareholders </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Calibri;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Company Launches www.AlkermesValue.com, Providing Additional Information for Shareholders</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Calibri;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Alkermes&#8217; Board Recommends Shareholders Vote &#8220;FOR&#8221; Alkermes&#8217; Director Nominees on Company&#8217;s <font style="text-decoration:underline;">WHITE</font> Proxy Card</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">DUBLIN, MAY 25, 2023 &#8211; <font style="font-weight:normal;">Alkermes plc (Nasdaq: ALKS) (the Company) today filed its definitive proxy statement with the U.S. Securities and Exchange Commission (SEC) and issued a letter to its shareholders in connection with the Company&#8217;s upcoming 2023 Annual General Meeting of Shareholders (the Annual Meeting), which is scheduled to be held on June 29, 2023. The letter details the Company&#8217;s successful execution and value creation since the announcement of its Value Enhancement Plan in December 2020. The Value Enhancement Plan is comprised of a number of initiatives, including Board refreshment, evaluation of strategic opportunities and establishment of long-term profitability targets.&nbsp;&nbsp;Key highlights from the letter include that Alkermes:</font></p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><a name="_Hlk105930449"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Generated a share price increase of 49% since the Company announced its Value Enhancement Plan on December 10, 2020. Since then, the Company&#8217;s total shareholder return (TSR) has outperformed its peers<sup style="font-size:85%;line-height:120%;vertical-align:top">1</sup><sup style="font-size:85%;line-height:120%;vertical-align:top"></sup> by 61%, the XBI biotech index by 83% and the NBI biotech index by 56%.<sup style="font-size:85%;line-height:120%;vertical-align:top">2</sup><sup style="font-size:85%;line-height:120%;vertical-align:top"></sup>&nbsp;&nbsp;Alkermes&#8217; TSR has also outperformed its peers and the XBI and NBI on a 1-year and 3-year trailing basis and other relevant timeframes. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Appointed seven new independent directors to the Company&#8217;s board of directors (the Board) over the last four years, while five longer-serving directors have retired. The newly appointed directors, which comprise 70% of the Board&#8217;s independent directors, include a director designated by activist hedge fund Sarissa Capital Management LP (Sarissa) in November 2021 (Cato T. Laurencin, M.D., Ph.D.), a director designated by Elliott Advisors (UK) (Elliott) in May 2021 (Emily Peterson Alva), and two directors appointed with the support of Elliott in December 2020 (David A. Daglio and Brian P. McKeon). </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Enhanced the Company&#8217;s corporate governance based on shareholder feedback, the evolving needs of the business and trends in governance best practices. These actions included, among others: declassifying the Board and establishing a plurality voting standard for contested director elections; forming the Financial Operating Committee of the Board to oversee achievement of the Company&#8217;s profitability targets; refreshing the Board&#8217;s Lead Independent Director and the membership and leadership of the Nominating and Corporate Governance Committee of the Board; enhancing the Company&#8217;s executive compensation programs; and limiting the number of public company boards on which directors may serve.</font></p></td></tr></table></div>
<div align="left"><table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:20%;"><tr><td style="width:20%;"></td></tr><tr><td valign="top"  style="border-bottom:Solid 1pt #000000;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;text-indent:0pt;font-size:8pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-style:italic;font-size:8pt;font-family:Calibri;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:italic;font-size:8pt;font-family:Calibri;font-weight:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">1</sup>&nbsp;</font></p></td>
<td valign="top" style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-style:italic;font-size:8pt;font-family:Calibri;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:normal;"> </font>Peers include: Acadia Pharmaceuticals Inc., Alnylam Pharmaceuticals, Inc., Blueprint Medicines Corporation, Emergent BioSolutions Inc., Exelixis, Inc., Horizon Therapeutics plc, Incyte Corporation, Ionis Pharmaceuticals, Inc., Ironwood Pharmaceuticals, Inc., Jazz Pharmaceuticals&#160;plc, Neurocrine Biosciences, Inc., PTC Therapeutics, Inc., Sage Therapeutics, Inc.<font style="font-weight:bold;">,</font> Sarepta Therapeutics, Inc., Ultragenyx Pharmaceutical Inc., United Therapeutics Corporation.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-style:italic;font-size:8pt;font-family:Calibri;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:italic;font-size:8pt;font-family:Calibri;font-weight:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">2</sup>&nbsp;</font></p></td>
<td valign="top" style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-style:italic;font-size:8pt;font-family:Calibri;font-weight:normal;text-transform:none;font-variant: normal;"> Share prices from 12/9/2020, the last trading day before Alkermes announced its Value Enhancement Plan, through 2/3/2023, the last trading day prior to Sarissa&#8217;s Schedule 13D/A disclosing its notice of director nominations.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Expanded its commercial portfolio by securing regulatory approvals of two new Alkermes-developed products (LYBALVI&#174; and VUMERITY&#174;) and grew net sales of its proprietary products, and advanced and expanded its pipeline under a disciplined and integrated development approach. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Initiated the separation of the Company&#8217;s oncology business from its neuroscience business and, in connection with this transaction, submitted a confidential draft Form 10 in April 2023.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-top:0pt;margin-bottom:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-top:0pt;margin-bottom:8pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:0pt;margin-bottom:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Drove strong performance and business momentum through a focus on operational efficiency, disciplined capital allocation, and profitability, including by calibrating Alkermes&#8217; cost structure to appropriately support the Company&#8217;s strategic priorities and growth opportunities. </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Despite the Company&#8217;s positive momentum and strong performance over this timeframe, Sarissa notified Alkermes in February 2023 of its intent to nominate three director candidates for election at the Annual Meeting.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">The Board recommends that shareholders vote &#8220;FOR&#8221; all seven of the Board&#8217;s director nominees &#8211; Emily Peterson Alva, Cato T. Laurencin, M.D., Ph.D., Brian P. McKeon, Christopher I. Wright, M.D., Ph.D., Shane M. Cooke, Richard B. Gaynor, M.D. and Richard F. Pops &#8211; using the Company&#8217;s WHITE proxy card.</font> The Company&#8217;s proxy statement and other important information and resources related to the Annual Meeting can be found at www.AlkermesValue.com or investor.alkermes.com/investor-relations. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The full text of the letter being sent to shareholders follows:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dear Alkermes Shareholder,</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Your vote at the Alkermes plc (the &#8220;Company&#8221; or &#8220;Alkermes&#8221;) Annual General Meeting of Shareholders (the &#8220;Annual Meeting&#8221;) on June 29, 2023 is very important. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Alkermes is a fully integrated, global biopharmaceutical company focused on developing innovative new medicines to address unmet patient needs and on driving long-term, sustainable value for its shareholders. In 2019, driven by the Company&#8217;s share performance, operational considerations, and shareholder feedback, the Company&#8217;s board of directors (the &#8220;Board&#8221;) and management recognized the need to realign the Company&#8217;s priorities, refine its strategic and operational focus, and effect certain governance changes. The Board initiated significant Board refreshment efforts and, in December 2020, announced its Value Enhancement Plan, which is comprised of a number of initiatives, including continued Board refreshment, evaluation of strategic opportunities and establishment of long-term profitability targets.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Alkermes&#8217; strong performance since the announcement of the December 2020 Value Enhancement Plan is a direct result of the Company&#8217;s execution against its three strategic priorities, as overseen by its recently refreshed Board: </p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Growing its portfolio of proprietary commercial products.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Advancing its development pipeline.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;">3.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Driving profitability for the benefit of its shareholders. </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For each of these strategic priorities, Alkermes has established clear objectives designed to drive shareholder value, including, for 2023:&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Drive the launch and continued uptake of LYBALVI&#174; through execution of the Company&#8217;s commercial strategy.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Advance ALKS 2680, the Company&#8217;s orexin 2 receptor agonist, including by establishing its initial safety and tolerability profile and generating clinical proof-of-concept data.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><a name="_Hlk135892752"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Separate the Company&#8217;s oncology business from its neuroscience business, which the Board believes will unlock shareholder value by enhancing the performance of both businesses and accelerating profitability for the neuroscience business. </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Underpinning these priorities and objectives and the operation of the business is the Company&#8217;s foundation of strong corporate governance, dedication to patients and employees, and its commitment to operating in an ethical and responsible manner.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ALKERMES HAS HAD STRONG RECENT PERFORMANCE AND MOMENTUM</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has been focused on evolving its business and establishing a strong foundation to drive shareholder value. These efforts began prior to activist hedge fund Sarissa Capital Management LP (&#8220;Sarissa&#8221;) becoming a shareholder of Alkermes. Since the Company announced its Value Enhancement Plan in December 2020, Alkermes&#8217; share price has increased by 49%, and the Company has outperformed its peers1 by 61%, the XBI biotech index by 83% and the NBI biotech index by 56%.2 Alkermes&#8217; total shareholder return (&#8220;TSR&#8221;) has also outperformed its peers and the XBI and NBI over various other timeframes, including on a 1-year and 3-year trailing basis.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:102.31%;">
<tr>
<td style="width:102.31%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gto1qxx111dr000001.jpg" title="" alt="" style="width:624px;height:310px;"></p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since the announcement of the December 2020 Value Enhancement Plan, the Company&#8217;s enterprise value to a next twelve-month revenue multiple has increased by approximately 51% from 2.5x to 3.8x, reflecting investors&#8217; recognition of the Company&#8217;s performance and future prospects.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Despite the Company&#8217;s positive momentum and strong execution of its business strategy over this timeframe, Sarissa notified Alkermes in February 2023 of its intent to nominate three director candidates for election at the Annual Meeting. This is the third year in a row Sarissa has submitted nominations to the Company, following a settlement in 2021 that resulted in the appointment to the Board of a Sarissa-designated director (who continues to serve on the Board) and Sarissa&#8217;s abandonment of its previous proxy campaign in 2022. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Earlier this year, the Board conducted its annual evaluation of the desired mix of skills, experiences and diversity of perspectives to support the Company&#8217;s strategic priorities, and the four independent directors on the Board&#8217;s Nominating and Corporate Governance Committee interviewed and carefully considered all of Sarissa&#8217;s candidates. Following the committee&#8217;s evaluation, the Board determined that the key attributes and experience of the three Sarissa nominees were neither additive to the Board at this time nor consistent with the skillset previously identified by the Board as important in a new director. The Board therefore determined that appointing Sarissa&#8217;s nominees as directors would not be in the best interests of the Company and its shareholders. Notwithstanding the foregoing decision, the Alkermes Board has made numerous attempts to reach a resolution with Sarissa and a number of the Company&#8217;s independent directors have continued to discuss with Sarissa ways to prevent a proxy contest.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ALKERMES HAS A REFRESHED, HIGHLY ENGAGED, </font><font style="font-weight:bold;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">DIVERSE</font><font style="font-weight:bold;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> AND INDEPENDENT BOARD WITH STRONG GOVERNANCE</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Alkermes has active, skilled and highly experienced Board members who are deeply engaged in oversight of the Company and its strategy. Starting in 2019, the Board initiated significant Board refreshment efforts and implemented new initiatives to enhance its corporate governance, its compensation programs and its business. Since that time<font style="font-weight:bold;">, Alkermes has appointed seven new independent directors to the Board and five longer-serving directors have retired</font>. None of the new, independent directors appointed had any previous connections to the Company or its leadership team. These new directors, who comprise 70% of the Board&#8217;s independent directors, include a director designated by Sarissa in November 2021 (Cato T. Laurencin, M.D., Ph.D.), a director designated by Elliott in May 2021 (Emily Peterson Alva), and two directors appointed with the support of Elliott in December 2020 (David A. Daglio and Brian P. McKeon). In 2022, in connection with its Board refreshment efforts, Alkermes appointed Nancy J. Wysenski as its new Lead Independent Director. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Board refreshment efforts added diverse backgrounds, skills, experiences, and perspectives to the Board that are relevant to the Company&#8217;s industry and operations and aligned with its business strategy. The Board is comprised of individuals with extensive experience in a variety of areas that are critical to the Company&#8217;s business strategy, including life sciences industry experience; commercial marketing and sales experience; finance and accounting experience; management and governance experience; buyside investor perspective and experience; and corporate strategy and complex transactional experience.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Alkermes maintains strong corporate governance and Board oversight practices that promote the long-term interests of its shareholders.<font style="font-weight:normal;"> The Company and the Board regularly engage with shareholders in respect of governance and other matters and the Board continually reviews and, as it deems appropriate, refines its governance policies and practices. As a result of shareholder feedback, the evolving needs of the business and trends in governance best practices, the Board has, in recent years, taken the following actions, among others, to enhance Alkermes&#8217; corporate governance, including: </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-style:italic;font-size:10pt;color:#000000;">Declassified the Board: </font><font style="font-size:10pt;color:#000000;">In July 2020, the Company announced its plans to declassify the Board and, at the Company&#8217;s 2021 annual meeting, the Company&#8217;s shareholders approved the declassification of the Board over a three-year period. This process will be completed next year. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-style:italic;font-size:10pt;color:#000000;">Adopted Plurality Voting for Contested Elections:</font><font style="font-size:10pt;color:#000000;"> In May 2022, the Board convened an Extraordinary General Meeting of Shareholders at which, at the Board&#8217;s recommendation, the Company&#8217;s shareholders approved the establishment of a plurality voting standard for contested director elections.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-style:italic;font-size:10pt;color:#000000;">Formed the Financial Operating Committee of the Board</font><font style="font-size:10pt;color:#000000;">: In December 2020, the Board formed the Financial Operating Committee of the Board, on which all three Elliott-supported directors serve, to oversee achievement of the Company&#8217;s profitability targets and evaluate a broad range of potential strategic options related to the Company&#8217;s non-core assets, including potential monetization and divestiture opportunities.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-style:italic;font-size:10pt;color:#000000;">Refreshed the Nominating and Corporate Governance Committee</font><font style="font-size:10pt;color:#000000;">: During 2022, the Board added three new independent committee members and appointed a new committee chair. All four members of the committee are diverse in terms of gender and/or race/ethnicity. Two members of the committee, including Sarissa&#8217;s director designee, were appointed to the Board in collaboration with shareholders.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-style:italic;font-size:10pt;color:#000000;">Enhancements to Executive Compensation Programs: </font><font style="font-size:10pt;color:#000000;">Since 2019, the Board has engaged in a concerted multi-year effort to solicit and respond to shareholder feedback related to the Company&#8217;s executive compensation programs. Shareholder feedback received through these engagement efforts led to the implementation of meaningful changes to Alkermes&#8217; executive compensation programs and other governance changes.</font></p></td></tr></table></div>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-style:italic;font-size:10pt;color:#000000;">Limited the Number of Public Company Boards on Which Directors May Serve:</font><font style="font-size:10pt;color:#000000;"> In May 2022, the Board revised its &#8220;overboarding&#8221; policy to further limit the number of public company boards on which the Company&#8217;s directors may serve, including that the Company&#8217;s CEO or other employee directors may serve on a maximum of one outside public company board and the Company&#8217;s non-employee directors may serve on a maximum of three other public company boards (in addition to the Alkermes Board).</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;margin-left:7.69%;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ALKERMES EXPANDED ITS PORTFOLIO OF PRODUCTS AND ADVANCED ITS PIPELINE PROGRAMS&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Alkermes has been consistently executing on numerous initiatives to drive shareholder value. The Company has successfully expanded its commercial portfolio by securing regulatory approvals of two new Alkermes-developed products, grown its revenues from proprietary products, and advanced and expanded its pipeline under a new, disciplined development approach. These achievements include: </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Two New Product Approvals</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">In 2021, secured U.S. Food and Drug Administration (&#8220;FDA&#8221;) approval and launched LYBALVI, an oral medicine for the treatment of schizophrenia and bipolar I disorder. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">In 2019, secured FDA approval of VUMERITY&#174; for the treatment of relapsing forms of multiple sclerosis, and supported Biogen&#8217;s commercial launch of this product. </font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;margin-left:7.69%;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Growth of Proprietary Commercial Product Portfolio</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Grew proprietary commercial product net sales from $524 Million in 2019 to $777 million in 2022, representing growth of 48%.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Generated strong initial uptake of LYBALVI that exceeded analyst expectations in the first year of launch; through the first quarter of 2023, more than 9,300 healthcare providers had written a prescription for LYBALVI and more than 115,000 prescriptions for LYBALVI had been dispensed.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Re-established VIVITROL&#174; growth in the addiction treatment system following COVID-19-related disruptions, and redefined VIVITROL&#8217;s commercial strategy in the alcohol dependence indication.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Drove growth of ARISTADA&#174;, including, most recently, 10% year-over-year growth in the first quarter of 2023. </font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;margin-left:7.69%;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Advancement of Neuroscience and Oncology Development Pipeline</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Initiated phase 1 first-in-human study for ALKS 2680, Alkermes&#8217; orexin 2 receptor agonist, enrolling initial cohorts and dosing subjects well ahead of anticipated timelines, with initial clinical proof-of-concept data expected before year-end 2023.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Advanced nemvaleukin alfa (&#8220;nemvaleukin&#8221;) into potential registrational trials in two tumor types and secured both FDA Fast Track designation for nemvaleukin in mucosal melanoma and in combination with pembrolizumab in platinum-resistant ovarian cancer, and FDA Orphan Drug designation for nemvaleukin in mucosal melanoma.</font></p></td></tr></table></div>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:7.69%;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Active Management of Royalty and Manufacturing Business</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Secured multiple successful interim awards in the Company&#8217;s binding arbitration proceedings against Janssen Pharmaceutica N.V. (&#8220;Janssen&#8220;), a subsidiary of Johnson &amp; Johnson, related to its partial termination of two license agreements with the Company and Janssen&#8217;s decision to cease paying royalties on certain products in the U.S. Pursuant to the interim awards, the arbitration panel found that, notwithstanding its termination of the license agreements, Janssen must continue to pay the Company royalties on the applicable products in the U.S. and that the Company is entitled to such royalties for 15 years from first commercial sale of each such product. Sarissa previously cited the Janssen dispute as a reason for deciding to submit a nomination notice in 2022. Alkermes expects to receive a final award in due course and plans to update its 2023 financial expectations accordingly.</font></p></td></tr></table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">THE ALKERMES BOARD AND MANAGEMENT TEAM HAVE BEEN DRIVING CHANGE FOCUSED ON OPERATIONAL EFFICIENCY, DISCIPLINED CAPITAL ALLOCATION, AND PROFITABILITY</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Board and Alkermes&#8217; management team have been keenly focused on the following objectives to best position Alkermes for long-term growth and value creation:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Execute on the Company&#8217;s December 2020 Value Enhancement Plan.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Drive operational efficiency and calibrate Alkermes&#8217; cost structure to appropriately support the Company&#8217;s strategic priorities and growth opportunities. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Work toward the planned separation of the oncology business.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Alkermes has taken substantial actions to optimize its cost structure over the past four years in response to the evolving needs of the Company and shareholder feedback, and in support of its commitment to driving shareholder value creation.<font style="font-weight:normal;"> </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_Hlk135693526"></a>Value Enhancement Plan. <font style="font-weight:normal;font-style:normal;">The December 2020 Value Enhancement Plan is comprised of a number of initiatives, including Board refreshment, evaluation of strategic opportunities and establishment of long-term profitability targets. This Plan was informed by direct engagement with, and feedback from, many of Alkermes&#8217; largest institutional shareholders throughout 2019 and 2020. Announcement of the Plan followed constructive dialogue and entry into a cooperation agreement with Elliott.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;">Cost Structure Optimization. <font style="font-weight:normal;font-style:normal;">In 2019, prior to its interactions with Sarissa or Elliott, Alkermes implemented a restructuring, which included headcount reductions and other cost-saving measures. In addition, in 2020, the Company adopted a revised research and development (&#8220;R&amp;D&#8221;) capital allocation strategy focused on prioritizing R&amp;D programs that it believes offer the highest potential return on investment. That disciplined strategy resulted in the discontinuation of several early-stage development programs based on data-driven decision making against pre-defined success criteria and R&amp;D stage-gates. In 2020, Alkermes implemented a reorganization of the Company&#8217;s commercial organization in preparation for the launch of LYBALVI, consolidating several functional areas to drive operating leverage and allocating resources to effectively drive growth. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;">Separation of the Oncology Business. <font style="font-weight:normal;font-style:normal;">In November 2022, following a robust evaluation process, Alkermes announced the planned separation of its oncology business from its neuroscience business.&nbsp;&nbsp;The Company submitted a confidential draft Form 10 for this transaction in April 2023 and expects the separation to be completed in the second half of 2023. The Board unanimously agreed that the unique needs of each business would be best served by simplified resource and capital allocation decision making, tailored operating structures, and distinct leadership teams, each with a clearly defined strategic focus. Following the planned separation of the oncology business, Alkermes will be a pure-play, commercial-stage neuroscience company, retaining its focus on significant unmet needs within neuroscience and on driving growth of its proprietary commercial products: LYBALVI, ARISTADA/ARISTADA INITIO&#174;, and VIVITROL. The separated oncology business, recently named Mural Oncology, will be a pure-play oncology company, focused on the discovery and development of cancer therapies, including the continued development of nemvaleukin and the Company&#8217;s portfolio of novel, preclinical engineered cytokines, comprised of tumor-targeted split interleukin-12 (IL-12) and interleukin-18 (IL-18).</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;">Accelerated Profitability Targets*. <font style="font-weight:normal;font-style:normal;">In February 2023, the Company accelerated its long-term profitability targets to reflect the anticipated financial benefit of the planned separation of the oncology business in the second half of 2023, and announced its commitment to achieving the following:</font></p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">FY 2024 non-GAAP net income equal to 25% of the Company&#8217;s total revenues and EBITDA<sup style="font-size:85%;line-height:120%;vertical-align:top">3</sup><sup style="font-size:85%;line-height:120%;vertical-align:top"></sup> margin of 20% of total revenues</font></p></td></tr></table></div>
<div align="left"><table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:20%;"><tr><td style="width:20%;"></td></tr><tr><td valign="top"  style="border-bottom:Solid 1pt #000000;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;text-indent:0pt;font-size:8pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-style:italic;font-size:8pt;font-family:Calibri;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:italic;font-size:8pt;font-family:Calibri;font-weight:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">3</sup>&nbsp;</font></p></td>
<td valign="top" style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-style:italic;font-size:8pt;font-family:Calibri;font-weight:normal;text-transform:none;font-variant: normal;"> Calculated as earnings before interest, taxation, depreciation, amortization and one-time items, includes share-based compensation expenses.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">FY 2025 non-GAAP net income equal to 30% of the Company&#8217;s total revenues and EBITDA margin of 25% of total revenues</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;margin-left:7.69%;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company did not provide reconciliations of, or comparable GAAP measures for, the above non-GAAP profitability targets, as they are not determinable without unreasonable efforts.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;line-height:9pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ALKERMES&#8217; PROGRESS, BUSINESS MOMENTUM, AND POTENTIAL HAS BEEN RECOGNIZED BY SELL-SIDE ANALYSTS</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;line-height:9pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk135911938"></a>Recent commentary from sell-side analysts includes:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;line-height:9pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-style:italic;font-family:Calibri;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&#8220;ALKS clearly has the flexibility to not only effectuate the spin-out of a funded oncology business but also execute on the addition of assets that can bolster the neuropsychiatry pipeline. We believe that ALKS is well-positioned for meaningful further value creation.&#8221;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8211; David Amsellem, Piper Sandler (April 26, 2023)</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-style:italic;">Regarding the arbitration with J&amp;J, we are not surprised that Alkermes won this case. We have never understood why J&amp;J believed that it didn&#8217;t owe Alkermes the appropriate and usual CM/royalties and that it could try to get out of this agreement. . . Regarding the decision to hive off the oncology business, we remain very supportive that this is a good move</font>.&#8221;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8211; Marc Goodman, SVB Securities (April 26, 2023) </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-style:italic;font-family:Calibri;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&#8220;We remain bullish on ALKS. We continue to believe the planned separation would unlock value for the oncology business and the standalone neuroscience company, transforming it into a more attractive entity given the potential blockbuster opportunity from LYBALVI and ALKS 2680 (orexin 2 agonist) and the leaner operating cost structure.&#8221;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8211; Uy Ear, Mizuho (April 26, 2023)</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-style:italic;font-family:Calibri;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&#8220;Outperformance has been delivered, in our view, on an attractive combination of commercial delivery (solid 4Q22 commercial results and FY2023 guidance), the declaration of a more focused strategy (with the planned separation of the oncology and neuroscience businesses), and the emergence of a pipeline asset, ALKS 2680.&#8221;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8211; Chris Shibutani, MD, Goldman Sachs (April 18, 2023)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-style:italic;">ALKS put up one of its better Q&#8217;s in yrs. The &#8217;23 guide was solid&#8211;LYBALVI guide was ~5% higher vs cons. &amp; implies inflection in &#8217;23 likely on the back of DTC efforts&#8230;. This remains the best idea in our coverage given base business execution + blue sky upside w/OX2</font>.&#8221;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8211; Akash Tewari, Jefferies (February 16, 2023)</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-style:italic;">We agree with ALKS&#8217;s decision to focus the business on neuroscience&#8230;we see the company on the cusp of a significant transition with announced plans to separate the oncology effort into a separate business allowing more direct focus on achieving improved profitability for the neuroscience business</font>.&#8221;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8211; Jessica Fye, JP Morgan (February 14, 2023)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PLEASE VOTE USING THE COMPANY&#8217;S <font style="text-decoration:underline;">WHITE</font> PROXY CARD TODAY</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk105931008"></a><a name="_Hlk135912000"></a>The Board has nominated seven director nominees for re-election to the Board at the Annual Meeting: Emily Peterson Alva, Shane M. Cooke, Richard B. Gaynor, M.D., Cato T. Laurencin, M.D., Ph.D., Brian P. McKeon, Richard F. Pops and Christopher I. Wright, M.D., Ph.D. <font style="font-weight:bold;text-decoration:underline;">The Board recommends that shareholders vote &#8216;FOR&#8217; all seven of the Board&#8217;s director nominees using the WHITE proxy card.</font> The Company&#8217;s proxy statement and other important information and resources related to the Annual Meeting can be found at www.AlkermesValue.com. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are three easy ways to vote:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:99.89%;">
<tr>
<td style="width:33.29%;"></td>
<td style="width:33.3%;"></td>
<td style="width:33.3%;"></td>
</tr>
<tr style="height:25.15pt;">
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:5pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">BY INTERNET</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:5pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">BY TELEPHONE</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:5pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">BY MAIL</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Visit the website shown on your <font style="text-decoration:underline;">WHITE</font> proxy card</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dial the toll-free number shown on your <font style="text-decoration:underline;">WHITE</font> proxy card (available 24/7)</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mark, date, sign and return the <font style="text-decoration:underline;">WHITE</font> proxy card in the postage-paid envelope provided</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk135912046"></a>If you have any questions about how to vote your shares, or need assistance in voting, please contact the firm assisting Alkermes with the solicitation of proxies for the Annual Meeting: </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Innisfree M&amp;A Incorporated </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Toll-Free at (877) 750-8334 (toll-free for those calling from the U.S. and Canada) or</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">+1 (412) 232-3651 (for those calling from outside the U.S. and Canada)</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To learn more about Alkermes&#8217; Board nominees, business strategy, and strong recent performance, please visit www.AlkermesValue.com.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Alkermes looks forward to communicating with you further as the Annual Meeting approaches, and as always, appreciates your continued support. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sincerely,</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Alkermes Board of Directors</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">About Alkermes plc</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Alkermes plc is a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for cancer and neurological disorders. Headquartered in Dublin, Ireland, Alkermes has a research and development center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes&#8217; website at www.alkermes.com.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Forward-Looking Statements</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk135728321"></a><a name="_Hlk135688527"></a>Certain statements set forth in this press release constitute &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning the Company&#8217;s expectations concerning its future financial and operating performance, business plans or prospects, including its ability to execute on its strategy and create and deliver growth and shareholder value and its ability to achieve long-term profitability and its profitability targets; the Company&#8217;s engagement with Sarissa<a name="_Hlk135728321"></a>; <a name="_Hlk135688527"></a>expectations with respect to the final award in the Company&#8217;s arbitration proceedings with Janssen and the Company&#8217;s plans to update its 2023 financial expectations; expectations regarding the timing, structure, anticipated benefits and other impacts of the planned separation of the Company&#8217;s oncology business; timelines, plans and expectations for development activities relating to ALKS 2680; and the therapeutic and commercial potential of the Company&#8217;s products. The Company cautions that forward-looking statements are inherently uncertain. The forward-looking statements are neither promises nor guarantees and they are necessarily subject to a high degree of uncertainty and risk. Actual performance and results may differ materially from those expressed or implied in the forward-looking statements due to various risks and uncertainties, including that the Company may not ultimately separate its oncology business during 2023 or at all; unanticipated developments, costs or </p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">difficulties that may delay or otherwise negatively affect a potential separation of the Company's neuroscience and oncology businesses; the Company may not be able to achieve long-term profitability or its profitability targets in a timely manner or at all; the terms of the final award to be issued in the Company&#8217;s arbitration proceedings with Janssen may differ from the terms of the interim awards issued in such arbitration proceedings and may be challenged by Janssen; clinical development activities may not be completed on time or at all; the results of the Company&#8217;s development activities may not be positive, or predictive of final results from such activities, results of future development activities or real-world results; the&#160;FDA or regulatory authorities outside the&#160;U.S.&#160;may not agree with the Company&#8217;s regulatory approval strategies or components of the Company&#8217;s marketing applications;&#160;the FDA or regulatory authorities outside the&#160;U.S.&#160;may make adverse decisions regarding the Company&#8217;s products; the Company and its licensees may not be able to continue to successfully commercialize their products or support revenue growth from such products; the Company&#8217;s products may prove difficult to manufacture, be precluded from commercialization by the proprietary rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; and</font><font style="font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> those risks and uncertainties described under the heading &#8220;Risk Factors&#8221; in the Company&#8217;s Annual Report on Form 10-K for the year ended Dec. 31, 2022 and in subsequent filings made by the Company with the SEC, which are available on the SEC&#8217;s website at www.sec.gov. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by law, the Company disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Important Additional Information and Where to Find It</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has filed its definitive proxy statement, accompanying <font style="text-decoration:underline;">WHITE</font> proxy card and other relevant documents with the SEC in connection with the solicitation of proxies for the Annual Meeting. BEFORE MAKING ANY VOTING DECISION, SHAREHOLDERS OF THE COMPANY ARE URGED TO READ ALL RELEVANT DOCUMENTS FILED WITH OR FURNISHED TO THE SEC, INCLUDING THE COMPANY&#8217;S DEFINITIVE PROXY STATEMENT AND ANY AMENDMENTS AND SUPPLEMENTS THERETO, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Investors and shareholders will be able to obtain a copy of the definitive proxy statement and other documents filed by the Company with the SEC free of charge from the SEC&#8217;s website at www.sec.gov. In addition, copies will be available at no charge by visiting the &#8220;Investors&#8221; section of the Company&#8217;s website at www.alkermes.com, as soon as reasonably practicable after such materials are filed with, or furnished to, the SEC.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Certain Information Regarding Participants in the Solicitation</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company, its directors and certain of its executive officers are participants in the solicitation of proxies from shareholders in respect of the Annual Meeting. Information regarding the names of such participants and their respective interests in the Company, by security holdings or otherwise, is set forth in the Company&#8217;s definitive proxy statement for the Annual Meeting, which can be obtained free of charge from the sources indicated above.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Non-GAAP Financial Measures</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This press release includes information about certain financial measures that are not prepared in accordance with GAAP, including non-GAAP net income margin (non-GAAP net income/total revenue) and EBITDA margin (EBITDA/total revenue). These non-GAAP measures are not based on any standardized methodology prescribed by GAAP and are not necessarily comparable to similar measures presented by other companies. Non-GAAP net income adjusts for certain one-time and non-cash charges by excluding from GAAP results: share-based compensation expense; amortization; depreciation; non-cash net interest expense; change in the fair value of contingent consideration; certain other one-time or non-cash items; and the income tax effect of these reconciling items.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s management and Board utilize these non-GAAP financial measures to evaluate the Company&#8217;s performance. The Company provides these non-GAAP financial measures of the Company&#8217;s performance to investors because management believes that these non-GAAP financial measures, when viewed with the Company&#8217;s results under GAAP and the accompanying reconciliations, are useful in identifying underlying trends in ongoing operations. However, non-GAAP net income margin and EBITDA margin are not measures of financial performance under GAAP and, accordingly, should not be considered as alternatives to GAAP measures as indicators of operating performance. Further, non-GAAP net income margin and EBITDA margin should not be considered measures of the Company&#8217;s liquidity.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*The Company has not provided full financial expectations for time periods after the year ending&#160;Dec. 31, 2023&#160;and therefore is not providing reconciliations of, or comparable GAAP measures for, non-GAAP net income margins or EBITDA margins, for time periods after the year ending&#160;Dec. 31, 2023. Reconciliations of such forward-looking non-GAAP profitability measures to comparable GAAP measures are not determinable without unreasonable efforts due to the inherent difficulty in forecasting and quantifying certain future financial amounts necessary for such reconciliations, which amounts could have a significant impact on the Company&#8217;s future financial results, including such non-GAAP profitability measures and the comparable GAAP financial measures.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contacts:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For Investors:&nbsp;&nbsp;Sandy Coombs, +1 781 609 6377</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For Media:&nbsp;&nbsp;Katie Joyce, +1 781 249 8927</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Or </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FGS Global </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chris Kittredge / Zachary Tramonti </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">alkermes@fgsglobal.com</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>gto1qxx111dr000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gto1qxx111dr000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +'!9<# 2(  A$! Q$!_\0
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#8\+?\C):?\
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MB_\ BJ;:6X6;.4HK9U3PGKNBQ&74-,FBB'608=1]64D"L:A.X@HHHH ****
M"BNW3X:7[^%/[<%[!S;?:A!M.=F-WWO7'M7$4DT]AM-!1113$%%%6=.LSJ&I
MVED'V&XF2(.1G;N8#./QH K45V7C+P&?"5E;7/\ :0NQ-(8]OD;-O&<_>.:X
MVA--70VK!1110(**** "BBB@ HHHH **** -CPM_R,EI_P #_P#0&HH\+?\
M(R6G_ __ $!J*SGN7'8QZ***T("BBB@ HHHH **** "BBB@#NOA3I/V_Q7]M
M<'RK&,R=,@NWRJ/_ $(_\!KUFRU>RU^YUK2L!A:2?9Y1V967G]=X_"N>^&^F
M2:/X'>^6!I+J[#7"QYP7 &$7\<9_X%6)X TGQ-I'BN:XU'3KA+>]1Q.Y88#Y
MW!CSZY'_  *L)>\VS6.B1YIJVGR:3J]WI\N=UO*T>2,;@#P?Q&#^->U?"_\
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MI+:*&+>JJ&)R5 X/'4BN4_X6?X1_Z!]S_P" R?\ Q58PDTM$:R2;W-/XF_\
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M(Z@CL?\ /K5OQ3XIUG_A-;R5;Z5/L5V\<"(Q"JJL0..^<<^M>B?%A5D\%(Y
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M/>?!J[CMV>SU>*>8#(CDA,8/X[C_ "KM;32;Y/AO:Z=H[PVM])9Q@.[$!68
MN<J"<\M@CO6'X)\$>(?#&N&YN;VSDLY499HXYG))Z@X*@$Y_0FI<WO<KE1Y,
MNDW7]MQZ3,GD733K 5D_A8G'/MSVKKYOA/KD>HV]K'-;2)*K,\XW!(@,=>.I
MSP![UH^-X((OBSHSQ!0\SVSRX/\ %YFWG_@(6NF^*6L7VD^'8%L9V@:YF\MW
M3AMN"< ]NE4Y/2W47*M;G*ZE\'[ZVL7FLM2CNYD&?):'RRWL#N//UQ63\.O#
M=SJ^O+?1RQQ+ID\4DJ.#ELDG ]_E/6NQ^$.J7E[IVHVMS.\L=NZ-$78DKN#9
M&3V^4<>YKCM-N[JR^*DMO:W,T$,VKE)8XY"JNHE/# =1R>OK2O+5,++1GHWC
MWP==^+?[/^RW,,'V7S-WF@\[MN,8_P!VO#;^S?3]2NK*1E:2WF>)F7H2I(./
MRKUGXMZIJ&F_V/\ 8+^ZM?,\[?Y$S)NQY>,X/.,G\Z\@DD>61I)'9Y')9F8Y
M+$]23ZTZ=["G:YL^#_\ D<M'_P"ON/\ ]"%>A_&;_CPTG_KK)_(5YYX/_P"1
MRT?_ *^X_P#T(5[GXH\2:5X<AMI-4@DE69F"!(U?!&,]2/6E-VDAQ^%GC/PZ
M_P"1]TO_ 'G_ /1;5UGQH_UNB_[LW_LE=)HGCWPYK&L6]A8V<\=S,2$9H$4#
M )/(/H#7-_&C_6Z+_NS?^R47;FKA:T65TTGQ>WP[\]=>B&E_8S)]FV_/Y6,[
M=VW/3C&<=NE<IX6\'ZCXKGD%J4BMXL>9/)G:">P'<UZO#_R1P_\ 8(;_ - -
M8?PCUNQ33+G1Y95BNVG,R!B!Y@*J,#U(V]/<>]"D[-H+*Z*-W\&KN.W9[35X
MIY@,B.2 Q@_CN/\ *K/PH\-W,,O_  D#31>1+%) (AG<#N'/I_":@U;X>>(-
M"N9=4\/ZG-<,"7*ABL^,]/1^.O3/I53X27MV?$LMDUS.;46SN(#(=@;<O.WI
MGWH;;B]0LE+8Z'Q[X#OM?U235K>[MXXXK8*4DSD[<GL/>O,_#GA?4O%%XT%@
MBA(QF6:0X2,=L^Y]!76_%/5]2M?%'V6VU"[AMWM%W0QS,J-DL#D XYKJ_ )A
MT?X8G4UBRVR>YD ZN4+#^2"A-QB%DY&!_P *8E\K/]N)YF/N_93C/UW?TKA?
M$?AC4?#%\MM?HI5QF*:/)20=\'U'<?XBB+Q5K<6LKJAU&X:Y#[FS(=K#.=I'
M3;[=*]:^*=M'=^"#<E1O@FCD0GJ,_*1_X]^E.\HM)BLFM#SK3OA]JFJ^&8M:
MM)8)!*2$M^=Y(?9Z8ZC/6KGB'X:W'A[PV^JS:E%+)&5$D*Q$ ;B!PV>>3Z"N
M]\$WAT_X4P7H3>;>"XE"$XW;7D.,_A7D&I^*=;U<7"7NHSR0SL&>'>?+&#D
M+T %"<FP:21V=WI/B\?#Q;B77HGTLVB2_9MOS^60"%W;<]".,X[5Q7A_P[J'
MB74/L=@BDJ-TDCG"QKZD_P!!S7L6H?\ )'$_[!,/_H"U6^$EE'!X4DN@!YES
M<,6..RX '\S^-)3M%L?+=HP3\&+C[/N&MQ&;'W#;G;G_ 'MV?TKCK3P;JMYX
MHG\/QB$74&3(Y?Y%48^;/7'([9YJ&\\4ZS<ZU+J8U&YCF9R4V2$!!GA0/3VJ
MQH^H^)M3\237.E32R:K=(RR2(J@E>,YR,*.!SQVJES):LGW>AV,?P8F,0,NN
M(LF.56V+#\]P_E7&^*?!^H>%+B-;HI+!-GRIX\X..H([&NHB^&/BT7L=^=3L
MA=JXD$CW$C-NSGD[#GFNE^+P!\(6Y(Y%ZF/^^'J5)W2O<IQ5MB[\-O\ DGMI
M]9O_ $-J\$KWOX;?\D]M/K-_Z&U>"4X?$Q2V1M^#O^1RT?\ Z^X_YUZW\2/$
MFI^&[*PETV5(VFD97W(&R !ZUY)X._Y'+1_^ON/^=>X>+/#ND^(K>VCU6\DM
MDA<LACE5,DCG[P-*=N97'&_*[%+P)XGE\7Z+=#4;>+S8F\J4*OR2*P]#^((K
MR*_\-W$WC6]T32H3*RW#K&N<!5SGD]@!WKU0:SX4^'^AO;6-RD\F2XACE$DD
MKG^\1P.W/' XS67\*$>_NM<URY"M<7$P7=CD9RS >QROY4D[7DAM7LC/@^#-
MPT -QK44<W=8[<NOYEA_*N,\3>$]2\+7*1WH1XI?]7/&<JWJ/8^U=YKOP_\
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M:KSZIJ%U:QVMQ?7,UO%CRXI)F9$P,# )P.*2@[J_0.9'N'PV_P"2>VGUF_\
M0VKP2KEOJ^IVELUM;:C=PV[9W11SLJG/7(!Q5.JC&S;$W=(V_!__ ".6C_\
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M # '<&O3Z "BBB@ HHHH ***\J\6?'31O#NJW6EV>G7.HW5K(8I3O$488'#
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M !QX6FU/4H+:&>.[>#;;*P4@*C X8DY^;UKMZ "BBB@ HHHH **** "BBB@
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ME\!F.VP" @]6Y/'K@=FQZS;01VMK#;Q#$<2!$'H ,"@"6BBB@ HHHH ****
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MHHBO%=4AL[62-0L;F-',A;&X@#<>3C\JS-!_Y.@O?^NL_P#Z)-2Q_P#)V'_
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M3]5M]0U"2)EMXK5_,&X\ LPX '7DY]* .$^ 'B(V-CXBM+V;9I]I$+XLW2,
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MJ?\ "7?$#P%X^TS3/%.HPZE:7S(&" %-K-M+*=JD,I[8Q^>:;H'_ "<_?_\
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M_FN=V[[WRD[1GV%&I>#/#^L:_::Y?Z<LVI6>SR)_-==NUMR\ @'!.>0:WJ*
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M  %    '  I:* "N4UCX:^$-?U=]5U/1DGO9-N^3SI%#8  RJL > .U=710
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MGK#IMWO\^#S';?O7:V6))Y4 =:W** ,KP_X:TCPKIS6&BV8M;5I#*4\QGRQ
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M1110 4444 .3[XHH3[XHH ;1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 .3[XHH3[XHH ;1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 .3[XHH3[XHH ;1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 .3[XHH3[XHH ;1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 .3[XHH3[XHH ;1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 .3[XHH3[XHH ;11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !14<D\,+(LLL:,YP@9@"Q]!ZU)0 44R.:*7=Y<B/L;:
MVU@=I]#[T2RQPQF2618T'5G. /QH ?12;EV[LC;C.<\8IB3PR0^<DL;18)WA
M@5P.O- $E%9EIXCT/4+HVMEK.G7-P.L4-TCN/P!S6G0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !39)$AB>65U2-%+,[' 4#J2>PIU>>?$&^NM>U.S\!:1,4N
M-0'FZE.AYM[0'YN1T+= #UZ'[V: .UTW6M*UA9&TO4[.^6,@.;6=90I/3.TG
M%4M?\7^'_"X7^V=5M[1G&5C8EG8>H1<MCCKBO/O@U9P:?XD\>V5JGEV]OJ?D
MQ)G[JJ\H _(4OPSL[/7?&/C/6=4CCNM3BU%K9!,H8P1 L% ';IC/^S]: /2=
M%U_2?$5E]KTB_@O(.A:)LE3Z,.JGV(%9^J^._"^B:K'IFI:W:V]X^/W;$G9G
MIN(&$Z_Q$5Q*6L7A;]H&TMM,C2"SUW3W>X@0;4#H'.X <9_=C_OIO6LNTU71
M=*T/XCZ=X@N+:+5KB^NV\J? DN$9/W.P'EAGH!TSGB@#VM'61%=&#*PR&!R"
M*H:5KFFZVMRVFW2W*6T[6\KHIVB0=0"1@]1R,BO-QJ6LP^"?#'@FP=D\1ZC8
MQB:0@@V-MC#2-W# ?*/<'OBO1M!T.Q\-Z):Z3IT>RVMDVKG&YCW9L=23DGZT
M :5%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% #D^^**$^^** &T444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <7\3KZ[L/#5O+97
M4]M(;Q5+PR%"1L?C([<#\J\G_P"$EU[_ *#>I?\ @6_^->H?%G_D5;7_ *_4
M_P#0'KQNNBFERF,WJ=OX#US5KSQII\%UJE[/"_F;HY;AV4XC8C()QUKVFO!_
MAW_R/>F_]M?_ $4]>S>(=8A\/^'M0U>?F.T@:7;G&X@<+]2<#\:SJ[EPV/&O
MB#877COQ+XDN+"9EA\*6*^0Z,1FXW"1\>X567CNJUZ[X1UU/$WA/3-83&;F
M-(!T5QPX_!@17E7@"Z\?Z1X<:>V\%QZG_:LK7\E[+J44;3F0 @E2<CC''N:T
M?@U=WFCZEKW@S5;3[#=VTOVV"U+ARD;XR PX(&4Z?WC699H_"3_D(>-_^P]-
M_,UH?&?_ ))1K/\ VP_]')6?\)/^0AXW_P"P]-_,UH?&?_DE&L_]L/\ T<E
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M163RQ(LL<D3[)(I%^ZZMV(JGH'@VQT'4)]2^VZAJ.HS1"%KO4)_-D$8.=@P
M ,\]* .BHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH <GWQ10GWQ10 VBBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"AJVBZ?KMJ
MMKJ5OY\*.)%7>RX8 C.5(/0FL;_A7?A7_H%?^3$O_P 57444U)K85D8.G>#/
M#^DW\=]8V'E7$6=C^=(V,@@\%B.A-3>)_#5EXLT1])U"2X2UD=7<0.%+;3D
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M@?1C1R20^9'54445(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** ')]\44)]\44 -HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **K6NH65\TZVEY;W#6\ABF
M$,H<QN.JM@\$>AJSG/2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ KYDN?\ CZF_WV_G7TW7S)<_\?4W^^W\ZVH]
M3.H14445L9!1110 4444 %%%% !78?#+_D=(?^N,G\JX^NP^&7_(Z0_]<9/Y
M4I_"QQW/<****Y#H"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M,7A_3+'19].FD7[7=LT[P^62'557 ..0#CG';FL_669OV6HRQ)/V2V'/H+A
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MZ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>VG@"ROH8+MKN6[FWM,T>PA!]U<9/3)Y[YZ5V5% '-Z+X3&C^+O$&O"],O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M&3^5<?78?#+_ )'2'_KC)_*E/X6..Y[A1117(= 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #D^^**$^^**
M &T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !7S)<_\ 'U-_OM_.OINOF2Y_X^IO]]OYUM1ZF=0BHHHK8R"BBB@
MHHHH **** "NP^&7_(Z0_P#7&3^5<?78?#+_ )'2'_KC)_*E/X6..Y[A1117
M(= 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% #D^^**$^^** &T444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 5-0U*STN!9[V811LVP-M)YP3C
M@>QK-_X3'0/^@@/^_3_X5G_$/_D7X/\ KZ7_ -!>O,ZZZ.'C./,SS\3BYTJG
M+%(]CL_$ND:A=I:VMX))GSM78PS@9/4>@J_>W2V5A<7;*66")I"HZD*"<?I7
ME?@O_D;;'_MI_P"BVKTK7_\ D7-4_P"O27_T UE7IJG*R-\+6E6@Y2[G+?#S
MXEVOCT74)L6T^]MP)/(:7S-\9Z.IVCOP>.X]:UM5\6#3/&VA>'/L1D.JI,WV
MCS<>5Y:EONX^;./48KQK1K*ZT'X<^$OB%I<9>XTTS0W\:_\ +:V-Q(#GZ9Q[
M9!_AKM];O[;5/BY\/+^SE$MM<6UU+&X[J8B16)TFUXH\=ZEHWBZT\.:1X;.K
MWEQ:?:A_IJP8 9@1\RD?PYZ]Z-%^(4UQXE@\.^(?#]UH>J7*,]NKS+-%* "2
M ZX&< ]NV.N,\UXQU.\TGXY:/=6.E3ZI.-&91;0,%8@O)DY/I5"YU^XUKXM>
M&I_%.DW'AVWLPXL4G4O]IF?  +@ +_#Z],=^ #T;Q#XN&@^)?#NCFR,_]LRR
M1>:)=OD[=O.,'=G=ZBNFKS+XB?\ )3/AW_U]S_\ M.O3: "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@"CJFHMIMNDJV5U=EGV[+:/<PX/)'IQ63_ ,)7-_T+NL_^ QKI
M** .;_X2N;_H7=9_\!C7D<OA+7))I'&F7@#,2/\ 1W_PKZ HJHR<=A-)[GSY
M_P (?KO_ $#;O_P'?_"C_A#]=_Z!MW_X#O\ X5]!T57M)"Y(GSY_PA^N_P#0
M-N__  '?_"C_ (0_7?\ H&W?_@._^%?0=%'M)!R1/GS_ (0_7?\ H&W?_@._
M^%'_  A^N_\ 0-N__ =_\*^@Z*/:2#DB?/G_  A^N_\ 0-N__ =_\*/^$/UW
M_H&W?_@._P#A7T'11[20<D3Y\_X0_7?^@;=_^ [_ .%;OA'2]6\/:_'J%QI&
MH21JC*5CMWSR/<5[-12=235@44CF_P#A*YO^A=UG_P !C1_PE<W_ $+NL_\
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M_"Q]._Y\KS\E_P :\YHKL^IQ[GG?VC+^4]&_X6/IW_/E>?DO^-'_  L?3O\
MGRO/R7_&O.:*/J<>X?VC+^4]&_X6/IW_ #Y7GY+_ (T?\+'T[_GRO/R7_&O.
M:*/J<>X?VC+^4]&_X6/IW_/E>?DO^-'_  L?3O\ GRO/R7_&O.:*/J<>X?VC
M+^4]&_X6/IW_ #Y7GY+_ (T?\+'T[_GRO/R7_&O.:*/J<>X?VC+^4]1A\9?:
M85F@T+5I8F^Z\<&X'MU%2?\ "5S?]"[K/_@,:F\%_P#(I6/_ &T_]&-6]7%-
M<LFCTZ<N:"EW,;3M>DO[Q;=M'U*V!!/F3P[5&/>MFBBI*"BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH <GWQ10GWQ10
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH <GWQ10GWQ10 VBBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M["N%\)Z3?ZYXBN/&GB"UFMIB&M]*L)TVM:09Y=@>DC]_0>QX ,#0M6N?!_\
M:.DZ3H%UXBU2V<77B#4$N$B!F<;CLW<N0,@* .GJ37H^C:O8>*O#EOJ5IE[*
M]B)VN,$ Y#*?<'(/TKAHXM?\'>)?%+6OAZ[U:UUB475G+;.F%E*D,LNX@J,]
M^>/TUM T^?X>?"/R;J1&N=.LIKB3GY?,.Z3:#WY./>@#)^ \TC_#GRG;*V][
M-&GL/E;^;&O3:X'X-:4VE_#+33(")+LO=,#_ +1^7_QT*:[Z@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*&_L?XX^$M0CD,:ZG;36,X'20#E0?^!,GY"@#T^BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** ')]\44)]\44 -HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 Y/OBBA/OBB@!M
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 Y/OBBA
M/OBB@!M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M Y/OBBA/OBB@"QY2?W?UH\I/[OZT^B@!GE)_=_6CRD_N_K3Z* &>4G]W]:/*
M3^[^M/HH 9Y2?W?UH\I/[OZT^B@!GE)_=_6CRD_N_K3Z* &>4G]W]:/*3^[^
MM/HH 9Y2?W?UH\I/[OZT^B@!GE)_=_6CRD_N_K3Z* &>4G]W]:/*3^[^M/HH
M 9Y2?W?UH\I/[OZT^B@!GE)_=_6CRD_N_K3Z* &>4G]W]:/*3^[^M/HH 9Y2
M?W?UH\I/[OZT^B@!GE)_=_6CRD_N_K3Z* &>4G]W]:/*3^[^M/HH 9Y2?W?U
MH\I/[OZT^B@!GE)_=_6CRD_N_K3Z* &>4G]W]:/*3^[^M/HH 9Y2?W?UH\I/
M[OZT^B@!GE)_=_6CRD_N_K3Z* &>4G]W]:/*3^[^M/HH 9Y2?W?UH\I/[OZT
M^B@!GE)_=_6CRD_N_K3Z* &>4G]W]:/*3^[^M/HH 9Y2?W?UH\I/[OZT^B@!
MGE)_=_6CRD_N_K3Z* &>4G]W]:/*3^[^M/HH 9Y2?W?UH\I/[OZT^B@!GE)_
M=_6CRD_N_K3Z* &>4G]W]:/*3^[^M/HH 9Y2?W?UH\I/[OZT^B@!GE)_=_6C
MRD_N_K3Z* &>4G]W]:/*3^[^M/HH 9Y2?W?UH\I/[OZT^B@!GE)_=_6CRD_N
M_K3Z* &>4G]W]:/*3^[^M/HH 9Y2?W?UH\I/[OZT^B@!GE)_=_6CRD_N_K3Z
M* &>4G]W]:/*3^[^M/HH 9Y2?W?UH\I/[OZT^B@!GE)_=_6CRD_N_K3Z* &>
M4G]W]:/*3^[^M/HH 9Y2?W?UH\I/[OZT^B@!GE)_=_6CRD_N_K3Z* &>4G]W
M]:/*3^[^M/HH 9Y2?W?UH\I/[OZT^B@!GE)_=_6CRD_N_K3Z* &>4G]W]:/*
M3^[^M/HH 9Y2?W?UH\I/[OZT^B@!GE)_=_6CRD_N_K3Z* &>4G]W]:/*3^[^
MM/HH 9Y2?W?UH\I/[OZT^B@!GE)_=_6CRD_N_K3Z* &>4G]W]:/*3^[^M/HH
M 9Y2?W?UH\I/[OZT^B@!GE)_=_6CRD_N_K3Z* &>4G]W]:/*3^[^M/HH 9Y2
M?W?UH\I/[OZT^B@!GE)_=_6CRD_N_K3Z* &>4G]W]:/*3^[^M/HH 9Y2?W?U
MH\I/[OZT^B@!GE)_=_6CRD_N_K3Z* &>4G]W]:/*3^[^M/HH 9Y2?W?UH\I/
M[OZT^B@!GE)_=_6CRD_N_K3Z* &>4G]W]:/*3^[^M/HH 9Y2?W?UH\I/[OZT
M^B@!GE)_=_6CRD_N_K3Z* &>4G]W]:/*3^[^M/HH 9Y2?W?UH\I/[OZT^B@!
MGE)_=_6CRD_N_K3Z* &>4G]W]:/*3^[^M/HH 9Y2?W?UH\I/[OZT^B@!GE)_
M=_6CRD_N_K3Z* &>4G]W]:/*3^[^M/HH 9Y2?W?UH\I/[OZT^B@!GE)_=_6C
MRD_N_K3Z* &>4G]W]:/*3^[^M/HH 9Y2?W?UH\I/[OZT^B@!GE)_=_6CRD_N
M_K3Z* &>4G]W]:/*3^[^M/HH 9Y2?W?UH\I/[OZT^B@!GE)_=_6CRD_N_K3Z
M* &>4G]W]:/*3^[^M/HH 9Y2?W?UH\I/[OZT^B@!GE)_=_6CRD_N_K3Z* &>
M4G]W]:/*3^[^M/HH 9Y2?W?UH\I/[OZT^B@!GE)_=_6CRD_N_K3Z* &") <@
M?K13Z* .<\)WVIW;:W#JMS%<36>HF!&BB\M0ODQ/@#). 7;DDFJ_B?Q9?Z+X
M@T;1=,T:/4KO4TG=/,O/LZH(@I/.QLY!_2M+0_#W]B7%_,-5OKQKZ;SY1<B'
M'F;57<-D:X^5%&.G%<?XX@O[CXI>"H],O8K*Z,%_MGEM_.51L3/R[ESD>] '
M3>&/%,NNW6IZ=?:7+IFJ::\8N;9I1*N'!*,KC 8$ ]ATKHZ\R\3:+J7A#P#X
MNUN+5I[W7K^-&GO1'Y>Q%(0;$7.P*C,<Y)[U#I/@K4+34_#^I:1IGA[2H;>5
M3-=66H2RO>6[+AD;,*B0GA@2>HH ]3HKQ:T\/WGB^^\722Z3HNIW0U.YM%N;
M^^DCGM$4[8PBK"P0!<,"#SFKVL:%+J'B;X;Z/XCG6]D%G>+>-%(VRY*1Q'D\
M%E)4$YZ]Z /6Z*\U\5^#4AU&UO['1M+U72].T]H3HES)Y0B!<MYL605#$ CY
M@/N\&NT\,7=C?>%=)N=,BEAL)+2,V\4I)=$VC:"23D@<9R?J: )]*N[^\MYG
MU#3#I\B3NB1F=9=Z _*^5Z9].HJ_7BEU'YWPPUN+S)(]_BQEWQMM9<WJ\@]C
M[UT;>']+\*?$[PJFAVJV27]M>0W2QL<3+&BLI;)Y8$_>/)H ](KGM$\03ZIX
MH\2:5+#&D6E301Q.N<N'B#G/T)[5P_@71-!\0^'KCQ%XF@A.NG496O+B:8I)
M:2I*0B!L@QA0$P!BH=85GC^,(4$GR(3@>UJ#0!Z_17F/B*^M)/#_ ,.8TN8F
MDGU33Y(D#C<ZA#D@=<#(Y]Q3+31]%\3^.?&DGBB&*>6P>*&!9Y"!:VWE!@Z'
M(VY))+#&#WH [3P?KDWB/PS!JEQ%'%))-/&4CS@".9XQU]0H-;M>%122GX.^
M$[*VDCELK[7)8)VN+EHHYHC/.0KR*"0K$+DX/ZUV_A?PIJNB>,&OTL-%TC3)
MK,Q36.G7,CB60,"LFTQ( 0"03[T =]7.>,_%+^%-'BNH-.?4;R>80V]HDFPR
M-@L><'&%5CT[5>\/Z7H^D:8;70TB2S\Z1R(I3(-Y8[N23WSQVZ5PVMZMJE]\
M5T_LK0)-:M_#UF5=8YXX3%<W ZDR, W[M<8'3<<T >@Z/J<.M:+8ZI;9\F\@
M2= 3D@, <'W&<5=KQ'3M7U?0?AGXWT*.RDTW4M&:26VMEE#/!:SG>I#H2"5#
M.<@\8%=OI?A_P5X9LK35]/BMX'6R=DF@F.^ZB";G)P?WO W<YQUXH [>BO#!
M!;Q-X,US2_#6EZ';7FKVRVT\5Z7O)H7)!#@)@AE/(+L1WKI(-&T/Q-XY\9/X
MGBBGDL&AB@2>4@6ML80V]#D;,DL2PQ@]Z .@T+Q5JVL^%;75;?1DNKB6^DMY
M(8IUB$<2RNADR_7 4' Y.>*Z^O$-*\O_ (4UX>\J0R1_\)''L<MDL/MS8.>^
M:V_$<.E^(/$GB*W@\+:7>S:="BW^HZM>F(1YCRHB 5RH"\Y&T9S]: /5*X63
MQOKT^KZW:Z3X32_M])G\F63^TA')(=@;Y4*>AZ;JU?AY<377PZ\/33R-)*UA
M%N=CDGY0.37':-I6O:GXH\<1:5X@CTN!M2"2_P"A":0DQ)RK%P%./8T ='!X
M\BU,^$+C3(0UEK\DJ,900\6R-F(XXR&4@]179UY9XC\(Z7977P^\+QK-_9L=
MS/$P$A5I%\EV;<PQ]XYSC'!(I]G%IG@[Q_XGM+2W-MHHT%-1GM;?( 96=6*
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M&XE@!CN: /2**\0LYVO_ (>?#W3=3N';2+W47M[US,=LBHTGE1%NZDJH_P"
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M6.P<GW-=#0 4444 %%%% !1110 53GTJQN=4M-2FMD>\LU=;>8YS&' #8^H
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M1M.?4Y=1>SB:[FM_LLLC#.^+).TCH1DFL_2?!7AK0KN6ZTS1;.VGD!5G2/D
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MEI+YT#'/R/M*Y'X,1^-6J* */]CZ>=:.L&U0Z@;;[(9SG)BW;MGIC/-95OX
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M'8M()KJ1WN+N8# DF<[G('89.![ 4S6O _AOQ%?K?:MI45S=+&(A(793M!)
MX([DUT%% &/;>%=$L["RLK?3XTMK&X^TVT>YCY<O/S#)SGYCU]:N_P!EV0U@
MZM]G7[>;?[,9^<^5NW;?3&>:MT4 4(-$TRVMKVVCLH?(OIGFN8V7<LKO]\L#
MD'/ITK/TGP3X:T.^6]TW1[:WN5!5) "2@/4+DG:/IBM^B@#+.BQ6NCZA9:.5
ML);KSI%F5=VR:3),F#U.XYQ7FB?#G5;KPSIOA^3P_H.FS6QA$FN6MQNN!Y;
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M'RD]2HZ*3Z@"M^B@#E-<\&P7GA^^T;24AL(=6N_.U*12=[*Q!E*Y!&]@ O/
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MX=>\UU+M99M:EU8%9U$P;,<9;CY>,$* !QDX%=5J=[K-A\8KZ;1])35/^))
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MF@ZS=^,['4K'PS_8-PEZ)+_4(=05HKN 9W(8UP79LCEE!![UI_&'_DE&O?\
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M;+Q+X6\5:[=:5H::S8:O,ERA6\2!K>0(%8/NZJ< @C./2L_XHKJ]EI>@^(+
M0QZ_$YL/)0Y5S<IL*J>K;7"LOT)H CU[QUKNHZ)9ZCH.F1BS?7ELX[A=0"_:
M$2=4'&SA9#O4\G &><UU&H>+;_3H=+LWT%IO$.H^88].@N0R(J?>=YBH 4 K
MSC.3@ U2UOPI=6/@#2=(T*W2[GTB>TFCA9UB^T>2ZLWS'A2V"<GN:SO%7AK4
M_$ESH7B"X\.+/+;Q30W>CO?!)-KD%2DJD+N&T'&<'.,\9H ZCPUXH.N7.H:=
M>:?)IVKZ:Z+=VCR"0 .-R,CCAE(]@>#D"L/Q,;CQ%\0-/\(?;)[734T]]2OA
M;2F-[A=_EI'N7D+G)..HJ_X)T.#2FOYX_"QT)Y]BD/>BXDF"YQNPS!<9/0G.
M:B\3:+K4'BO3_%GA^"*\NH+9[*[L)91%]H@8[AM<@@,K<\]?4=P"S;:%H/@&
MTO\ 5[::\M-/AMV>:V:Y>6$8YW*KDD/QC@\YZ5EI\1-0MC:7NL^%+O3=#O9(
MXX;][J-V3>1L,L8YC!SZG'>I-4L_$GCCP[JVCZEHD6B6US:,D32WBSRF;*E"
M0@VA!@YY)/%9NIZ?XO\ &.BVGAK5O#T6FVOFP&^O_MR2+(D;!CY2+\P+%1C=
MC'O0!KZAXYU&/Q7J/A[2?#$^J75E'#*SK=)$FQQDDLPP#T '.[GH!3;GQUJD
MFL:QI6B^%+G4[G2YUCD8720QE&C5P=S#[W) 4 ],DC(K0T;2+ZT\?^*-4G@V
MV=]%9+;R;U.\QK('X!R,%AU Z\5RFFZCXBT[QMXU;1]!CU>%[^(%1=K \;^0
MG)W\%2,=.1@\'/ !T+_$/3W\*:9K5I97=S-JDWV:TL H69YLL"AR<*%*MEB<
M#%2:)XRO+K7DT+7]!DT74IH6GME-REQ'.BXW!77'S#/(QTYKG8_ ^NZ5X9\,
MW-JMM=ZYI%[+?3V_F>7'/YQ<R(K'H0'P">.*U;'3-<\0^-]-\1:UI T>WTFW
MFCM;<W232R22@*S-LRH4*.!G.: )/"OCG4O%/EW$'A:YBTW]ZDEXUTF/,0GY
M44X+@X W< $XYP33QXUU6SU33X=<\+3:;9:C<BTMK@7D<S+*V=@D1?NYP>0S
M8[U)X1T75]*^&RZ2X%GJHCN1&2P<1N\DC(V5R#]Y37"VG@C7'N_#4LGA:2"^
ML-0MYM0U*XU?SVN I^=U4L>"?FYP1T - '3:7K_BJ7XG>(-._LJ*;3X6M%PV
MH8%O$WF?O579\Q<#<5R,;0,GK5C3_$VEZ!H_BS59H+M8;36IHY$,YG>:4^6
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ME?,3 _O4FF^#]7@^)<DLL 7PW;75QJEJZRKA[F:-$*E.HVGSF!QCYJ -6_\
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MQL/S=5V^@SFLO^R/',W@;3_"C>';:)+"2U26[-\C"XCBE1LQKP0?E!.[' (
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M\8.Z^._ JJS ->W.X ]?W#5L^%?$+^)M,N+_ .Q&VMUNY8+=O,WBXC1MHE'
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M\M\@!X YY K8T/2KVS\:>*M0GAV6M\]J;9]X.\)"%;@'(P>.<54T?0]1M?\
MA,_.M]G]I7LDMK\ZGS%,**#P>.01SCI0!GP?$YY_[,U$>&[Z/PYJ$T=O'J<L
MJ*PD<[5S%DMLSQNS^!XSNZUK?B&RO7ATGPI)J,,:!GG>^C@#?[* Y+'ZA1[U
MS;^%M9/PE\/Z&+/_ (F-I)9-/#YJ?((Y59_FS@X /0_2HO$GAO6+_P 8:A<W
M>@R:]IT\<*Z>O]JFWBM"%P^],@\MSD!CT% &Y<_$"T_X1O1M3T[3[J^NM:(2
MQL%94D=MI)W$G"A<')YQQ4C^,KC3/#ESJ?B'0+K3;B&585M(Y4N#<.Y 01,I
M 8DG'(&*Y6U\&^(--\->![^WL(YM:\.><)+![A4$J2J5<*_*[A\I&3CK6OXE
MT;7_ !SX1F@O-'M],NH+J*YM;6:[$OF[#DB1DX4,"0,$XZYH T]+\7W[Z]:Z
M-K^@2:/=7T;R61%TEPDNP NA*@;7 .<<CK@FBQ\;"]\":IXF&GE/L"W;?9_.
MSO\ (+?Q;>-VWT.,]ZR/"OAJ"V\06UX? ;Z1) CD7<VJ"?8Q7:0BAFR""1D[
M?I62=#\9Z;X5\0^$;'0K>YM[MKLVVI/>HJF.;<=I3[WF?,0.BY(R<#D OZ]X
MI\2GQ-X-;2-+26VU"VEG-NU_Y8G8P[BC?(<;."#W/&!6Q'J5M;_$:X%[!+;7
M*>'TN[B4WA:&-/-8,NS&,@J3O[CM5#5-&U^SC\$ZEI^EK?W&BPM%<V0N$B<[
MX!&2K,=ORD>O/:K%YX;U'6?&5_=W5O\ 9K*_\,C3GD617\N9I'+*!G)P&ZXP
M: )]!\::KKUS:W$7A*]BT*\_X]]0:YC+$=F:'.Y5/8Y/TIFM^-M7T 7%_?>$
M[A-#MI=DMY]LC,NW.WS!",Y7)'\0..<5%X1?QAI5AI7AZ^\.6Z06,26TFI"_
M0QO&@"AEC W[B .#CGG/:N)U[P)XDU/2-5M+CPX^HZS+-(\>L3:O^[=#)N4)
M$6^4[<*%("C&<T =Y-(L7QC65SA$\..Q.,\"X6K/A7Q9J/B;R;P>'I+;1[J,
MR6MZ;N-V8 \;XQRA/;!;ISBG3Z7J2_$7^V8+59+9-#>V1FE"AIO-#!#U(! Z
MX(_E7/Z#X?U>+QQ::G9^'SX9T]4F.I0+>I+%>NP 3;&AVKM;YMV%)Z4 =3XO
M\4#PGIMK>&PGOOM%Y':B&W/[PE\\J,?,>.!QG/451TCQG=W'B5-"UW0)M%N[
MF)YK'?<I,MPBXW#*?=< Y*\\ \^M3XHF[72M!-@L+W@UVT,"S$A"^XX#$<@9
M]*BM-+U_Q'X\TG7]:T=='MM&@G6"+[6D[SRR@*3\O 0*#UP<XXH H^%?$4'A
MKX=+=26\UU//K%U;6MK !OGF>YDVJ">!T))/0 _2NO\ #NL:QJ9N(M9\.S:/
M/$%9<W*3QR*<_==>XQR".,CKFN.3PCX@B\%:<D%M"-5TS7I=4CM995"SIYLN
M%WC(4LDF0>QZUNS^+=9TOP[JVN:YX>CTV&S@#06SWRR23R<C;E 57)VJ.IR>
ME '8UXGX'U2[\/>*+F]N;B631M;UB[L9?,8D6]VLK&,C)X#J=O3JHS7LMG++
M<6-O-/ ;>:2-7DA+;O+8C)7/?!XS7"Z/X'FN_!/B#0M:A^SF_P!2NKB%E=6*
M!GW1R @G!! ..OK0!F^#O$-KX=T;X@ZSJDTAM;/Q)>DX.6/*!57)ZDD #@<U
MTMAXPU(:S8V&N^&YM)7469;*;[4DP9PI;9(%QL8J"0.1VS7$Z-\.O$M]\+_%
M.AZXT5OK&IZF]['*9%9)&_=L&.W. S(>V1GIVK;\.>&(H->L9Y?A\VFR0,7-
MX^K"98VVD HH8ELYQR%QF@#I-%\6C6-/\0W8LC%_8]_<V17S=WF^2!\V<#;G
M/3G'O6;??$&2TTGPO=P:%<7D^OQ!XK6WE&Y',0<+D@ C)P6.  ">V*RH=(\6
M:%)XHTG3-$@O+;6+ZXO8=1EO%1(O.495X_O$J0<8X/J*T-/\.ZK /AWYEKM_
ML>V:.^_>*?*8VOEXZ_-\W'RY_*@"Y?>,]1LH=-LAX:GG\1WT<DHTN*Z0K"B'
M!=YONA>1@XY)QC-&G>/H&M-9_MW3I]'OM&A$][;2.)1Y9!*M&Z\.#@CC'/%1
M^(],UNR\9V/BK0].CU-DLGL+JS:X$+E"X=61F^7((.03T_3*N/".N>++;Q1>
M:S#!I=SJMA'86=J)1*8$0LP,CKP27;MT'K0!O:!XIUO5KV$7WA&]TZPNDWVU
MT]S'(<8+#S4',9(^O)P<5EZ'XYO_ !;I4MROABZM]):WG6:]-XJX=0V508#$
M<8W@#!['&:U= U3Q?=W%M;:QX;M[".-,75W]M202L%/^J1>0"V#\V,#(YJ#P
M=H>HZ5\,H='O;?RK]8;A3%O5L%G<KR"1R&'>@#-L_&4>A>$_!JV>C7MXNKPA
M(8%N?-F0^5O +,!NYP"25 &3T&*UM#\;->76J6.O:4^AW^FP"ZFBDG69# <_
MO%=1@@;3GCCWK(T_PQK$%I\.$DM-K:.A%^/-0^2?LY3U^;YCCY<U;U+PK>ZK
MXXUR>1/*TW4/#_\ 9RW(921(7?/RYSP&!]/>@!D'Q$NV@L]6N_#-U:^'+V2-
M(=1>Y1G42$!'>(<JC%ASDGD<<UU>OLR>'-492586DI!!Y!V&O,=#\"FS@T_3
MM2\ +<3VYCCEU!=6'D/MQ^]V%MV>,[=F,UZEJ]O)=Z)?VT*[I9K:2-!G&6*D
M"@#PC29/#MAHW@VXT&:]LO$EQ/:)<SN\\4$@(!E$C2$1LI&<!<DG&*]6%]8V
M_P 2=3\U)XY+?1HYY9VN6,7E^8^?W6, C;G=[XXYSQTVC>,-<^&UGX'G\*BP
M MK>VEU"YOH9$C$94E@B$L3\O X^M=5<^%KR]\6ZT\JE=.O= 33EN2RDE]TF
M[Y<YX# YZ<T 43\3+V.Q379_"-_%X7?:PU)IXS($8@"0P#Y@G.<YSCG%:^K>
M,+R#Q$^B:)H3:M=06R75S_I:0!8V)"[-WWV.#Z#IEN:YB33O'%_X)3P3-H-K
M;K]F2QDU?[:CP^2N%+K']\L5'0XY/6M#QOH5[JC&VLO"1N;F&W\O3]8@U%8)
M+=\8!8Y5P%/.!N!]* -C7?&-Q8:M;Z)H^B3:KK4UM]K>U\](%AASMW/(V1DG
M@ 9Z'IQFI=:J+W7_  8U_I-]97MS/=*(7NMOD,D3%MRKE90=O'(X(/M5.?2/
M%.A>)K+Q!:6<>O2RZ1%I]_"LZ0.94;=YJE^""2V5X_&K]Q8:[JOB#P=JMYIL
M5LUE/=R7D<=PL@@5X71.3C<3E0=HZD]N: &7OCR]$^IR:3X:N-2TW2I7AO;L
M7*1'<G^L$2-S)M[Y*Y((&:DU7Q^EJ_A]=+TJXU;^W;>2>T6!PK?*J, =W !#
MY))&W;WKDW\!/IVK:N+CP;_;L-W>RW5O=0:GY&U9#N\N1&=>A)^89R*ZO_A'
M;F'Q)X-GL].2VT_3+.YBFC28,+<ND85 3RW*D9 [<XH ET7QU%=VVN#6[!]'
MO=#42:A;M*)PD90NKJZCY@5![9[8I- \7:QK%W:O<^$;VQTJ]7?;7KW$;D+M
M+ RQ@YC! XZ\D XS67/X-U+4?$7Q"\U!;V>NV-O;VEP65@66%D8E0<C!(ZXS
MVK0T"Z\73PV>D:QX;@M+>*'R;N^%\CK* A&8D4;ADX/S8P,]: *9^)4_]GG7
MD\.7#>%ED*G4_M*!RH;;YHAZE,]\YQSMK2U3QC>0^(YM$T30GU:YM8$N+H_:
MT@"(Y.T)N^^W!]!TYKA-*^';:5IT>CW_ ($&KR1$I_:":L(X9DW'#,A8,IQC
M("GI71^.]$U'6)I8;'PGYMY%!LT[6K?45@>W8CJW*N K<[1N!]LT >B*<J"0
M1D=#VKB?BO(\?@Q&1V4_VC:<J<?\MEK3L];NK?Q!IOAB=!>W:Z;]IOKU7VA&
M!" E,?QMN(Y'0\5!\0]&O]=\+K9Z=!YUP+VVE*;U7Y4E5F.20. ": (]<\97
M^G^*6\/:7X=GU6]-BEXA2X6) &D="'9AA0-HYY)SC'%%O\0+)O!UYK]Y8W5M
M)8SM:7-C@/*MP&">6N.&RS+@^_:K4>E7J_$VYU@P_P"@/HT5JLNX<R+-(Q7&
M<]&!SC'-<Q/X+UFZ\,^)K9(HH;^;Q"^JZ?YL@*2!6C9=VW. VUA@X([T =7X
M?US7-1NI(-9\+SZ1\ADBE^U1SHXR!M)7E7YZ8(X//%=#7-:9J_BF\^T27OA:
M.P2*W=HXGU!)'GFXVJ"HPJ]?F//(XZTV]\47U@WANUFT;_B9:Q,(YK1;H$VJ
MA=TC[@,.$XSC&<CF@"QXX9D^'_B1T8JRZ7=$,#@@^4U>6Z?'X?TR3P6_@W4"
MVO7<]L-0MK2]>99("H,QF3<P4#U(&#]./6?%EC<:GX-URPLX_,NKK3YX84W
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ML&+^6!;=Y=S<QJQ8#&<=6/.,U=HH **** "BBLO4->M-,UG2=+G64W&J/)'
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MD$J#UP2 <>PJ:B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *X+4?\
MDN6B?]@6X_\ 1@KO:H2:-I\NMPZR]N#J$$+6\<VYOEC8@D8SCJ!SC- '!Z]H
M-CXB^-5K9ZDLLEJOAYI'A25D67_2 -K[2-R\YQTR!6%>7%[X7^&WCVST6>X2
M/3]4^SVF926MH7$.X(QY 4.V/3K7K1T>P.NKK9@_XF*VQM!-O;_5%@VW&<?>
M&<XS38M"TR%=11;.-DU*0RWB29=9F*A#D-D8*J!CI0!Y]HOA75-/\3:/?Z5X
M:M-%MXW87TD>K-/]JB9",,NT;F!PP8DGBIO!GAG2[_Q#XDUR^26>ZM-?N!;;
MY6V08VDLJ@XR<\DYR !74:5X#\,Z)J,=_I^F"&XBW>43-(ZQ;@0=BLQ5,@D?
M*!UK7T_2K+2S=FRA\K[7<-=3_,3OE;&YN2<9P.!Q0!X?K4]G/H4/B_P]X:-C
M$VHQ-;:U+J)-S+^_"-F,Y)5OF&TMTYQ78:GHNE^(/C+>:?JY:6W.B02"T\YD
M28B63EE!&[;D\'CGITKH'^&7@V2>69M"@W2.)"!(X5&W!LHH;"$D#.T#/0\5
M0U;P':>(_'UY?:WIL5UI;Z9##$Y?:ZRK([':5(9>&'(QUQ0!Q-Q?WVC> /%6
MG:1/,=.M?$"V%O-]I(,$#-'O19#DJ 25SSC<?2NE\/>%]4TOQAIE[I_AVUT'
M3@DL>H+#J9G%R"GR$J5&6#@?-UP3S7<VOAS1K+0O[$M],MDTO:4-J8P48'KD
M'KGU-4-'\"^&] OEO=-TT17"*5C=YI)/+4]0@=B%'L,4 <;IEQ#!\)_&PFF2
M,QW6K1OO8#:Q9\*?<Y''N*I:MX?T?4]7^&)U#3[>X^U6S0SF1<^8BVVY5/J
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MBQ)8Y4<G)&,=*Y?PG\+=#@T;39]>T&U?6+=I#(Q;<K'S'*E@IVN0I&"0<=*
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M0G9PUHMU#MA"G@O)NV\C& ,GKZ56MO'MA_PCNKZKJ=M<:<^CR-%?6TFUV1P
M0%*G#!MRX/?- '645Y7KWB/4-6U3P=#J'AN_TDOKD,\#S,CJZ>5*,,5)V/\
M,/E//7T..@36;?1;GQUJ %].=,*SRQ37.Y#BV63;$,?("#SUYY]J .THKC+3
MQ^TNIZ9%>>'M1L-/U5_*LKZ<IB23:6 9 =R;@#C/)]!3->\?W&FMK#:;X>NM
M3MM&'^GW"SI$D9"!R%SRQ"D$X'% ';45G:#J<FLZ#9:G);"V-U$)5B$HDPIY
M4[AP<K@_C7$>(?'<FHZ!XA&G>']0N](@AN+234XF3:) A4E8\[F0'JP'KZ4
M>D45Q^E:IJ.G^"?#*:;H=QJDTNG0D^7-'$D8$:?>9SWSP #T-0/\1[:+P[+J
M\^FSVXLM373M3BED4&S8L%+DC(=1N7D=0: .WHK$O/$*6_BW3/#\5N9YKR"6
MYE=9 /L\:8 8CJ=S-M'XUSGQ3N_L$/A.Z,,\_E>(;=O*@3=(_P"[E^51W)H
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M6?F2QS1SA!EAN0D!@.<'\^E3Z=XPAU'P_K>K+:.BZ5/=0-&7!,AASD@]LXH
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M,4@8(Z_>4XZ$=Q4]<9I'@:./P?HND7U]?I]F4RW:6MPT/VF9\L^]DPQ&YF.
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M5)!X(Z&LGQ_%K^J7>DVVF^&KN[BT[5;:_:X6YMT21$R650T@;/..0!Q7?T4
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M<P(U[(.1&V^12L8/)]2/2N\MK.ULED6TMH8%DD:6011A0[L<LQQU)/4]ZGH
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MD@KOWC' 4Y4L#GD<<]'X4M]7M/"NFV^O7 N-4C@ N) <Y;W/<@8!/<C-;%%
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M10 5QMEXZNM5NFDTGPSJ%]HZ7)MCJ,<L2ABK;69$+;F0'/(]#795Y7KL%_\
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MO^!5PDKZ\WP\.M#PUJ@U+^T?^$C%V98#$.<@;?,W[?)PN-N?:@#W:J6L7_\
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MMT:%IB2Y7'&XGDMZD]ZTJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH .HP:Y2'X;>$+>[CN8M&0&.3S8XC-(84;.<B(ML'
MX+110!<UKP7X?\0WT=[J6G^9=(GEB:*:2%RG7:2C L/8Y%7+?P[I-I<V%Q;V
M212:?;M;6NQB!'&VW*XS@YVKR1GBBB@!\>AZ;'=ZE="T1I=3"K>;R668*NP
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
